...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of clinical virology: The official publication of the Pan American Society for Clinical Virology >A European multi-centre External Quality Assessment (EQA) study on phenotypic and genotypic methods used for Herpes Simplex Virus (HSV) drug resistance testing
【24h】

A European multi-centre External Quality Assessment (EQA) study on phenotypic and genotypic methods used for Herpes Simplex Virus (HSV) drug resistance testing

机译：欧洲多中心外部质量评估（EQA）研究单纯疱疹病毒（HSV）耐药性试验的表型和基因型方法研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Highlights ? First European EQA scheme for Herpes Simplex Virus phenotypic and genotypic drug resistance. ? Broad data concordance among participating labs was observed despite diverse testing strategies. ? Points of difference able to inform future schemes and help improve testing protocols. Abstract Background Herpes Simplex Virus (HSV) drug resistance is a significant public health concern among immunocompromised individuals. Phenotypic assays are considered the gold standard method for detecting HSV drug resistance. However, plaque reduction assays (PRAs) are technically demanding, often with long turnaround times of up to four weeks. In contrast, genotypic tests can be performed within a few days. Objectives The development and coordination of the first European External Quality Assessment (EQA) study to evaluate phenotypic and genotypic methods used for HSV drug resistance testing in specialised reference laboratories. Study design Four HSV-1 or HSV-2 strains with different antiviral susceptibility profiles were isolated from clinical samples. Isolates were quantified by qPCR, and aliquoted in culture medium. One isolate was distributed at two dilutions to help assess assay sensitivity. The panel was distributed to five European centres with a six-week deadline for the return of phenotypic and genotypic results, together with clinical reports. Results Four out of five participating labs returned results by the deadline. Limited results were later available from the fifth lab. Phenotypic and genotypic data were largely, but not completely, concordant. An unusual resistance profile shown by one of the samples was explained by the detection of a mixed virus population after extensive further investigation by one of the centres. Conclusions Discordant clinical outputs reflecting the diversity of phenotypic methodologies demonstrated the utility of this exercise. With emerging genotypic technologies looking to supplant phenotyping, there is a need for curated public databases, accessible interpretation tools and standardised control materials for quality management. By establishing a network of testing laboratories, we hope that this EQA scheme will facilitate ongoing progress in this area.
机译：强调 ？疱疹病毒表型和基因型耐药性的第一个欧洲EQA方案。还尽管有多样化的测试策略，但参与实验室之间的广泛数据一致性。还差异点能够通知未来的计划并有助于改善测试协议。摘要背景疱疹病毒（HSV）耐药性是免疫表明个人的重大公共健康问题。表型测定被认为是用于检测HSV耐药性的金标准方法。然而，斑块减少测定（PRA）在技术上要求苛刻，往往具有长达四周的长期周转时间。相反，基因型测试可以在几天内进行。目标第一欧洲外部质量评估（EQA）研究的发展和协调评估专业参考实验室中用于HSV耐药性试验的表型和基因型方法。研究设计4 HSV-1或HSV-2具有不同抗病毒敏感性谱的菌株与临床样品分离。通过QPCR定量分离物，并在培养基中等分。一个分离物以两种稀释液分布，以帮助评估测定敏感性。该小组分发给五个欧洲中心，六周后的表型和基因型结果与临床报告一起返回。结果五个参与实验室中有四个截止日期返回结果。结果有限，后来可以从第五个实验室获得。表型和基因型数据在很大程度上，但不是完全合作。通过在由其中一个中心进行广泛的进一步调查之后检测混合病毒群体，解释了其中一种样品的异常阻力曲线。结论反映表型方法的多样性不和谐的临床产出证明了这项运动的效用。随着展望取向剂表型的新出现基因型技术，需要策划公共数据库，可访问的解释工具和质量管理的标准化控制材料。通过建立一个测试实验室网络，我们希望这一方案将有助于该领域的持续进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号